What Is ctDNA?

Circulating Tumor DNA (ctDNA) refers to small fragments of DNA that are shed by cancer cells into the bloodstream. These fragments carry the same genetic mutations as the tumor itself, making them a valuable tool for detecting and monitoring cancer through a simple blood test.

ctDNA is one of the key components analyzed in a liquid biopsy.

 

How ctDNA Testing Is Used in Cancer

1. Early Detection (Emerging Use)

• Research is ongoing to use ctDNA as a tool for cancer screening and early detection.
• Currently, most applications are for patients already diagnosed with cancer.

2. Treatment Selection (Precision Medicine)

• ctDNA can be sequenced (often via NGS) to identify genetic mutations.
• Guides the choice of targeted therapy or immunotherapy.
• Examples:
  • EGFR mutations in lung cancer → EGFR inhibitors.
  • KRAS, NRAS, BRAF mutations in colorectal cancer → therapy guidance.

3. Monitoring Treatment Response

• ctDNA levels often decrease when treatment is working and rise when cancer is growing.
• Provides a real-time marker of how the tumor responds, sometimes earlier than imaging.

4. Minimal Residual Disease (MRD) Detection

• Detects very small amounts of cancer DNA after surgery or chemotherapy.
• Helps predict the risk of relapse before it is visible on scans.

5. Tracking Resistance

• Identifies new mutations that explain why a therapy stops working.
• Allows switching to a more effective treatment.

 

What to Expect During the Test

• A routine blood draw (similar to a standard blood test).
• Blood is processed to isolate DNA fragments, which are analyzed using NGS or PCR-based methods.
• Results are usually available within 1–3 weeks.

 

Benefits

• Non-invasive — only requires blood, no tissue biopsy.
• Can be repeated frequently for long-term monitoring.
• May detect recurrence earlier than imaging.
• Provides molecular information from multiple tumor sites (not just one biopsy).

 

Risks & Limitations

• Not all cancers release enough ctDNA to be detected.
• Very small tumors may not shed measurable ctDNA (false negatives).
• Some genetic changes found in blood may not come from cancer (e.g., clonal hematopoiesis).
• ctDNA tests are not yet standardized worldwide; coverage and availability may vary.
• Usually used with tissue biopsy and imaging, not as a replacement.

 

Alternatives & Related Tests

• Liquid Biopsy (blood-based): Broader term that includes ctDNA, CTCs, exosomes.
• Tissue Biopsy: Gold standard for diagnosis.
• NGS (Next-Generation Sequencing): Technology used to analyze ctDNA.
• Tumor Markers (CEA, CA-125, PSA): Older blood-based indicators, less specific.

 

Questions to Ask Your Doctor

• Is ctDNA testing appropriate for my cancer type?
• Will this test guide treatment decisions in my case?
• How often should ctDNA be checked during my treatment?
• Can ctDNA detect recurrence earlier than scans?
• Is this test covered by insurance or part of a clinical trial?

 

Patient Tips

• Keep copies of ctDNA reports for your records — they may guide future treatments.
• Understand that ctDNA complements, but does not replace, tissue biopsy and imaging.
• Ask if results will be used to guide clinical trial eligibility.
• If results show no ctDNA, it may still mean monitoring through other methods is required.

 

References

• National Cancer Institute (NCI): Circulating Tumor DNA
• American Cancer Society: Blood-Based Biomarkers
• Nature Reviews Cancer: “Clinical applications of circulating tumor DNA” (2019)